Evidence map›Paper›PMID 36736493›Full record

ArticleBioorganic & medicinal chemistry letters2023

Activity of N-phenylbenzamide analogs against the neglected disease pathogen, Schistosoma mansoni.

Masebe Kanyanta, Chilufya Lengwe, Dickson Mambwe, Karol R Francisco, Lawrence J Liu, Yujie Uli Sun, Dilini K Amarasinghe, Conor R Caffrey, Peter Mubanga Cheuka

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Masebe KanyantaDepartment of Chemistry, School of Natural Sciences, University of Zambia, P.O Box 32379, Lusaka, Zambia.
Chilufya LengweDepartment of Chemistry, School of Natural Sciences, University of Zambia, P.O Box 32379, Lusaka, Zambia.
Dickson MambweSchool of Medicine and Health Sciences, University of Lusaka, P.O Box 36711, Lusaka, Zambia.
Karol R FranciscoCenter for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Lawrence J LiuCenter for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Yujie Uli SunCenter for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Dilini K AmarasingheCenter for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: ccaffrey@health.ucsd.edu.
Peter Mubanga CheukaDepartment of Chemistry, School of Natural Sciences, University of Zambia, P.O Box 32379, Lusaka, Zambia. Electronic address: peter.cheuka@unza.zm.
University of California San Diego · USUniversity of Zambia · ZMUniversity of Lusaka · ZM

Funding

RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasisR21AI156554 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2021 to 2022
$435k
NIAID NIH HHS HHSN272201300014INIAID NIH HHS HHSN272201700014CNIAID NIH HHS R21 AI156554NIAID NIH HHS T32 AI007036
6 · The paper itself

Abstract

For the Schistosoma mansoni flatworm pathogen, we report a structure-activity relationship of 25 derivatives of the N-phenylbenzamide compound, 1 (MMV687807), a Medicines for Malaria Venture compound for which bioactivity was originally identified in 2018. Synthesized compounds were cross-screened against the HEK 293 mammalian cells. Compounds 9 and 11 were identified as fast-acting schistosomicidal compounds whereby adult worm integrity was severely compromised within 1 h. Against HEK 293 mammalian cells, both compounds exhibited high CC

Indexed as

Schistosomiasis mansoniSchistosomicidesAnimalsBenzamidesChlorine CompoundsFluorine CompoundsHEK293 CellsHumansNeglected DiseasesSchistosoma mansoniBenzamidesChlorine CompoundsFluorine CompoundsMMV687807SchistosomicidesAntischistosomal agentsN-phenylbenzamide analogsSchistosoma mansoni

Identifiers

PMID36736493
PMCPMC10072318
OpenAlexW4319216391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.